Health reform will make health insurance a less-profitable business, but WellPoint Inc. got a vote of confidence from bond analysts because health-reform rules have turned out milder than expected and WellPoint’s financial performance has been particularly strong as the economy recovers.
Premiums for private health insurers in China are expected to rise to $90 billion by 2020 from $9 billion now, and WellPoint Inc. is angling for a big piece of that pie.
Indiana University Health has canceled its plans for a $73 million administrative office building at 16th Street and Capitol Avenue and has instead purchased the Gateway Plaza tower at 10th and Illinois streets.
It was a good but not great year financially for three of the four largest hospital systems operating in the Indianapolis area last year—and hospital analysts are expecting several head winds to continue.
One year after President Obama signed the health reform overhaul, health insurers are buying less-regulated companies in a bid to offset the lower profits and growth they expect the law to cause.
In the face of new health reform restrictions, expect more small employers to opt for self-funded health benefits, concludes a report this week from Indianapolis-based United Benefit Advisors.
Drugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling.
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
Indiana wants to use its public health savings account program for low-income adults to cover people who will become newly eligible for Medicaid under the federal health care law beginning in 2014.
The Indianapolis-based insurer awarded Angela Braly a total pay package worth $13.4 million, up from $13.1 million in 2009 even as the company's profit and enrollment numbers slipped.
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Human resources used to be about payroll and benefits. Now it’s also about watching Congress.
Unusual home on south side has a dozen bedrooms for folks who need to give up their own homes.
Indiana University Health is the latest system to drill employees ranging from clerks to physicians in how to treat patients.
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
The Indianapolis-based company released more details this month about its Enlist Weed Control System, which would genetically modify corn, soybeans and cotton to be resistant to one of the most common weedkillers.
The Indianapolis-based life insurer pulled in sales last year of $1.7 billion and boosted its overall assets 12 percent, to $24.4 billion.
The state budget bill moving through the Indiana General Assembly would save about $7 million each year by creating a list of preferred mental health drugs and trying to win larger rebates from manufacturers.
Delays getting new diabetes meters into the U.S. market appear to have tripped up Roche Diagnostics Corp. on its way to acquiring a key software vendor.
